Clinical Trials

LymphoidOther hematologic neoplasm

Leukemia, Large Granular Lymphocytic, Lymphoma, Extranodal NK-T-Cell

NCT04554511 2023-06-18

Prognostic Nomogram of Extranodal NK/T-cell Lymphoma

Unknown

1,000 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT05907447 2023-06-18

A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types

Unknown

10,000 enrolled

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Extranodal NK-T-Cell

NCT05774028 2023-03-17

Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma

Lymphoma, Extranodal NK-T-Cell

NCT05426824 2022-06-22

The Whole-course Management of Pegaspargase in ENKTL

Phase NA Unknown

72 enrolled

Phase EARLY_PHASE1 Unknown

Lymphoma, Extranodal NK-T-Cell

NCT03646422 2022-03-31

AEDV Registry of Primary Cutaneous Lymphoma

Unknown

2,000 enrolled

DermatologicLymphoid

Sezary Syndrome, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Extranodal NK-T-Cell

NCT05208853 2022-01-26

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma

9 enrolled

Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

NCT03439501 2021-09-24

Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]

21 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT02631239 2021-08-25

MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma

Phase 3 Unknown

256 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT05008666 2021-08-17

Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH

37 enrolled

LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

NCT04999878 2021-08-11

RUE-DDGP

LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

NCT04917250 2021-06-08

GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

15 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT04899414 2021-05-24

Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma

Lymphoma, Extranodal NK-T-Cell

NCT02085655 2021-03-15

PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Phase 3 Unknown

264 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT04676789 2020-12-21

SPENT

Lymphoma, Extranodal NK-T-Cell

NCT02544425 2020-10-22

VIDL+ASCT

27 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT04490590 2020-07-29

A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma

Lymphoma, Extranodal NK-T-Cell

NCT04405375 2020-05-28

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

29 enrolled

LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

NCT04279379 2020-05-07

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Lymphoma, Extranodal NK-T-Cell

NCT04338282 2020-04-08

Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma

Lymphoma, Extranodal NK-T-Cell

NCT04337593 2020-04-07

Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL

Lymphoma, Extranodal NK-T-Cell

NCT04096690 2020-03-11

Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma

22 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT04008394 2019-08-07

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

Phase 1 Unknown

LymphoidOther hematologic neoplasm

Hodgkin Disease, Immunoblastic Lymphadenopathy, Recurrence, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT04038411 2019-07-30

PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma

Lymphoma, Extranodal NK-T-Cell

NCT03701022 2018-10-09

PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

61 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT03598959 2018-07-26

Tofacitinib Combined With Chidamide in R/R ENKTCL

Lymphoma, Extranodal NK-T-Cell

NCT03154918 2017-11-08

GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma

60 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT03107962 2017-04-11

Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma

Lymphoma, Extranodal NK-T-Cell

NCT03051542 2017-02-13

Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma

Phase NA Unknown

60 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT03051555 2017-02-13

18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma

Phase NA Unknown

60 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT02878278 2016-08-25

Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation

24 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT01991158 2016-06-14

GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma

Lymphoma, Extranodal NK-T-Cell

NCT02080234 2016-04-20

Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL

40 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT01501136 2015-07-17

CTTNKTL-I/II

200 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT01501149 2015-07-17

CTTNKTL-Ⅲ/Ⅳ

80 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT02134262 2014-11-06

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Phase 1/2 Unknown

18 enrolled